Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 9, 2005

View Archived Issues

Patupilone shows promise in the treatment of multiple myeloma

Preclinical and clinical neuroprotective efficacy of statins in cerebral vascular disease

Preclinical data published on NBI-42902, a GnRH receptor antagonist

New data on the antitumor effects and toxicity of thalidomide monotherapy in HCC

Celecoxib shows promise in the prevention of intraabdominal adhesions

Novartis inlicenses rebamipide for dry eye

Phenserine fails to achieve significant efficacy in phase III Alzheimer's study

Viragen seeks expansion of approval for Multiferon in Sweden

Novavax receives NIH grant for SARS vaccine work

Cardiovascular drug candidate RUS-3108 enters phase I in Ireland

Takeda to acquire Syrxx

Phase I program of tgAAC-09 for HIV/AIDS expands to India

Portola begins phase Ib trial for oral anticoagulant

New Eloxatin formulation receives FDA approval

RiVax ricin vaccine enters clinical testing

Neurocrine prepares resubmission of indiplon NDAs

Ligand earns milestone for initiation of phase II for SB-497115

Fujisawa inlicenses ACR-16 from Carlsson Research

Evidence suggests that antihypertensive drugs improve severity of ischemic stroke

Improved outcome found with rosiglitazone in diabetic patients with cardiovascular disease

Pioglitazone reported to decrease carotid artery intimal thickness in obese subjects

Fendrix hepatitis B vaccine approved in Europe

BBB-permeable metal chelator shows promise for Alzheimer's treatment

Aston University team presents novel CCK1, CCK2 modulators

New 11beta-HSD1 inhibitors described in recent Merck patent

CRTH2 receptor ligands and their use for respiratory disorders reported by AstraZeneca

Gemin X discloses series of agents with anticancer and antiviral properties

Hydroxyfasudil prodrugs emerge from Schering R&D

Cardioprotective agents in early development at Dongbu Hannong

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...